REKOVELLE PEN for S.C. Injection General Drug Use Survey (Controlled Ovarian Stimulation in Assisted Reproductive Technologies)

Last updated: August 6, 2024
Sponsor: Ferring Pharmaceuticals
Overall Status: Active - Recruiting

Phase

N/A

Condition

Infertility

Treatment

N/A

Clinical Study ID

NCT06545877
000409
  • Female

Study Summary

This survey targets controlled ovarian stimulation with this drug for the development of multiple oocytes in women undergoing assisted reproduction (ART) such as in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Participants who received the REKOVELLE in controlled ovarian stimulation inassisted reproductive technologies and have consented to participate in the survey.

Exclusion

Exclusion Criteria:

  • No exclusion criteria because data are collected under conditions of use in dailypractice.

Study Design

Total Participants: 500
Study Start date:
September 16, 2022
Estimated Completion Date:
June 22, 2029

Connect with a study center

  • Ferring Investigational Site

    Omitama, Ibaraki
    Japan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.